Marksans Pharma Limited (BOM:524404)

India · Delayed Price · Currency is INR

321.25

+0.65 (0.20%)

At close: Aug 21, 2026

76.95% (1Y)

Market Cap	145.60B +77.0%
Revenue (ttm)	31.72B +19.6%
Net Income	5.17B +47.6%
EPS	11.40 +47.2%
Shares Out	n/a
PE Ratio	28.18
Forward PE	24.80
Dividend	0.90 (0.27%)
Ex-Dividend Date	Aug 20, 2026

Volume	240,841
Open	321.60
Previous Close	320.60
Day's Range	312.85 - 326.60
52-Week Range	156.00 - 345.70
Beta	n/a
Analysts	Strong Buy
Price Target	324.33 (+0.96%)
Earnings Date	Aug 12, 2026

About Marksans Pharma

Marksans Pharma Limited, together with its subsidiaries, engages in the research, manufacturing, marketing, and sale of pharmaceutical formulations in the United States, North America, Europe, the United Kingdom, Australia, New Zealand, and internationally. The company offers products in the pain management, cardiovascular, central nervous system, anti-diabetic, gastrointestinal, analgesics, upper respiratory, ear care, skincare, anticancer, anti-ulcerative, anti-allergy, antiviral, dietary, cardiac, dermatology, antihistamines, anti-fungal, an... [Read more]

Industry Pharmaceutical Preparations

Founded 1992

Employees 1,685

Stock Exchange Bombay Stock Exchange

Ticker Symbol 524404

Full Company Profile

Financial Performance

In fiscal year 2026, Marksans Pharma's revenue was 29.51 billion, an increase of 12.51% compared to the previous year's 26.23 billion. Earnings were 4.18 billion, an increase of 9.81%.

Financial Statements

Analyst Summary

According to 3 analysts, the average rating for 524404 stock is "Strong Buy." The 12-month stock price target is ₹324.33, which is an increase of 0.96% from the latest price.

Price Target

₹324.33

(0.96% upside)

Analyst Consensus: Strong Buy

Stock Forecasts

News

Marksans Pharma Transcript: Q1 26/27

Q1 FY 2027 saw record revenue and profitability, driven by strong growth in Europe, North America, and Australia/NZ, with significant contributions from recent acquisitions. Management maintains cautious guidance due to geopolitical risks but targets doubling revenue in five years and continued expansion in Europe.

9 days ago - Transcripts

Marksans Pharma Quarterly report: Q1 2027

Marksans Pharma has published its Q1 2027 quarterly earnings report on August 13, 2026.

9 days ago - Filings

Marksans Pharma Slides: Q1 2027

Marksans Pharma has posted slides in relation to its Q1 2027 quarterly earnings report, which was published on August 13, 2026.

9 days ago - Filings

Marksans Pharma to acquire ABCnow GmbH for €892,384

Marksans Pharma Limited has announced its acquisition of ABCnow GmbH, a Germany-based pharmaceutical company, for a total cash consideration of €892,384. This strategic acquisition aims to enhance Mar...

6 weeks ago - Business Upturn

Marksans Pharma announces ₹0.90 per share final dividend for FY26

Marksans Pharma has announced a final dividend of ₹0.90 per equity share for the financial year ended 31 March 2026. This decision was made during the company's Board of Directors…

7 weeks ago - Business Upturn

Marksans Pharma announces 90% final dividend ahead of AGM

Marksans Pharma has announced a final dividend of ₹0.90 per equity share for the financial year ended 31 March 2026, subject to approval at the upcoming Annual General Meeting (AGM).…

7 weeks ago - Business Upturn

Marksans Pharma submits machine-readable financial results for March 2026

Marksans Pharma has addressed a compliance issue by submitting a machine-readable version of its financial results for the quarter and year ended March 31, 2026. This submission follows a notification...